Compare Nuwellis Inc (NUWE) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Uranium Energy Corp — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Uranium Energy Corp trades at $9.33 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 2059.1× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Uranium Energy Corp for 37 Days on average.
| NUWE | UEC | |
|---|---|---|
Market Cap | $2.20M | $4.53B |
Volume | 121,544 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $146.65 | $20.14 |
52-Week Low | $0.68 | $9.04 |
Typical Hold Time | 26 Days | 37 Days |
Enterprise Value | -$1.52M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a net income margin of -368.62% and has missed earnings expectations in recent quarters. However, the company is expanding production capacity with two operational mines and benefits from growing U.S. government demand for domestic uranium.
While analyst consensus remains strongly bullish with an 87.5% buy rating and $16.06 price target, fundamental challenges persist including negative cash flow from operations and unproven production sustainability. The stock faces execution risks as it scales operations, but long-term uranium demand tailwinds provide potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
